Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Trypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability Assessment.

Zmuda F, Shepherd SM, Ferguson MAJ, Gray DW, Torrie LS, De Rycker M.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01082-19. doi: 10.1128/AAC.01082-19. Print 2019 Oct.

2.

Identification of Novel Trypanosoma cruzi Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay.

Zmuda F, Sastry L, Shepherd SM, Jones D, Scott A, Craggs PD, Cortes A, Gray DW, Torrie LS, De Rycker M.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00309-19. doi: 10.1128/AAC.00309-19. Print 2019 Sep.

3.

Burkholderia pseudomallei d-alanine-d-alanine ligase; detailed characterisation and assessment of a potential antibiotic drug target.

Díaz-Sáez L, Torrie LS, McElroy SP, Gray D, Hunter WN.

FEBS J. 2019 Jul 1. doi: 10.1111/febs.14976. [Epub ahead of print]

PMID:
31260169
4.

Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase.

Torrie LS, Zuccotto F, Robinson DA, Gray DW, Gilbert IH, De Rycker M.

PLoS One. 2019 May 31;14(5):e0217828. doi: 10.1371/journal.pone.0217828. eCollection 2019.

5.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.

Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C, Norcross NR, Vinayak S, Anderson M, Brooks CF, Cooper CA, Damerow S, Delves M, Dowers K, Duffy J, Edwards TE, Hallyburton I, Horst BG, Hulverson MA, Ferguson L, Jiménez-Díaz MB, Jumani RS, Lorimer DD, Love MS, Maher S, Matthews H, McNamara CW, Miller P, O'Neill S, Ojo KK, Osuna-Cabello M, Pinto E, Post J, Riley J, Rottmann M, Sanz LM, Scullion P, Sharma A, Shepherd SM, Shishikura Y, Simeons FRC, Stebbins EE, Stojanovski L, Straschil U, Tamaki FK, Tamjar J, Torrie LS, Vantaux A, Witkowski B, Wittlin S, Yogavel M, Zuccotto F, Angulo-Barturen I, Sinden R, Baum J, Gamo FJ, Mäser P, Kyle DE, Winzeler EA, Myler PJ, Wyatt PG, Floyd D, Matthews D, Sharma A, Striepen B, Huston CD, Gray DW, Fairlamb AH, Pisliakov AV, Walpole C, Read KD, Van Voorhis WC, Gilbert IH.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7015-7020. doi: 10.1073/pnas.1814685116. Epub 2019 Mar 20.

6.

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.

Corpas-Lopez V, Moniz S, Thomas M, Wall RJ, Torrie LS, Zander-Dinse D, Tinti M, Brand S, Stojanovski L, Manthri S, Hallyburton I, Zuccotto F, Wyatt PG, De Rycker M, Horn D, Ferguson MAJ, Clos J, Read KD, Fairlamb AH, Gilbert IH, Wyllie S.

ACS Infect Dis. 2019 Jan 11;5(1):111-122. doi: 10.1021/acsinfecdis.8b00226. Epub 2018 Nov 12.

7.

A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors.

Harrison JR, Brand S, Smith V, Robinson DA, Thompson S, Smith A, Davies K, Mok N, Torrie LS, Collie I, Hallyburton I, Norval S, Simeons FRC, Stojanovski L, Frearson JA, Brenk R, Wyatt PG, Gilbert IH, Read KD.

J Med Chem. 2018 Sep 27;61(18):8374-8389. doi: 10.1021/acs.jmedchem.8b00884. Epub 2018 Sep 12.

8.

Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2018 Nov;16(11):714. doi: 10.1038/s41579-018-0085-1.

PMID:
30206344
9.

Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors.

Bayliss T, Robinson DA, Smith VC, Brand S, McElroy SP, Torrie LS, Mpamhanga C, Norval S, Stojanovski L, Brenk R, Frearson JA, Read KD, Gilbert IH, Wyatt PG.

J Med Chem. 2017 Dec 14;60(23):9790-9806. doi: 10.1021/acs.jmedchem.7b01255. Epub 2017 Nov 22.

10.

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani.

Torrie LS, Brand S, Robinson DA, Ko EJ, Stojanovski L, Simeons FRC, Wyllie S, Thomas J, Ellis L, Osuna-Cabello M, Epemolu O, Nühs A, Riley J, MacLean L, Manthri S, Read KD, Gilbert IH, Fairlamb AH, De Rycker M.

ACS Infect Dis. 2017 Oct 13;3(10):718-727. doi: 10.1021/acsinfecdis.7b00047. Epub 2017 Oct 2.

11.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2017 Jul;15(7):447. doi: 10.1038/nrmicro.2017.69. Epub 2017 Jun 5. No abstract available.

PMID:
28579611
12.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Field MC, Horn D, Fairlamb AH, Ferguson MA, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH.

Nat Rev Microbiol. 2017 Feb 27;15(4):217-231. doi: 10.1038/nrmicro.2016.193. [Epub ahead of print] Review. Erratum in: Nat Rev Microbiol. 2017 Jul;15(7):447. Nat Rev Microbiol. 2018 Nov;16(11):714.

13.

Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode.

Spinks D, Smith V, Thompson S, Robinson DA, Luksch T, Smith A, Torrie LS, McElroy S, Stojanovski L, Norval S, Collie IT, Hallyburton I, Rao B, Brand S, Brenk R, Frearson JA, Read KD, Wyatt PG, Gilbert IH.

ChemMedChem. 2015 Nov;10(11):1821-36. doi: 10.1002/cmdc.201500301. Epub 2015 Sep 23.

14.

N-myristoyltransferase is a cell wall target in Aspergillus fumigatus.

Fang W, Robinson DA, Raimi OG, Blair DE, Harrison JR, Lockhart DE, Torrie LS, Ruda GF, Wyatt PG, Gilbert IH, van Aalten DM.

ACS Chem Biol. 2015 Jun 19;10(6):1425-34. doi: 10.1021/cb5008647. Epub 2015 Feb 27.

15.

Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis.

Brand S, Norcross NR, Thompson S, Harrison JR, Smith VC, Robinson DA, Torrie LS, McElroy SP, Hallyburton I, Norval S, Scullion P, Stojanovski L, Simeons FR, van Aalten D, Frearson JA, Brenk R, Fairlamb AH, Ferguson MA, Wyatt PG, Gilbert IH, Read KD.

J Med Chem. 2014 Dec 11;57(23):9855-69. doi: 10.1021/jm500809c. Epub 2014 Nov 20.

16.

Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase.

Roberts AJ, Torrie LS, Wyllie S, Fairlamb AH.

Biochem J. 2014 Apr 15;459(2):323-32. doi: 10.1042/BJ20131033.

17.

A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.

McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, McLean WH.

PLoS Biol. 2013;11(6):e1001593. doi: 10.1371/journal.pbio.1001593. Epub 2013 Jun 25.

18.

Allosteric competitive inhibitors of the glucose-1-phosphate thymidylyltransferase (RmlA) from Pseudomonas aeruginosa.

Alphey MS, Pirrie L, Torrie LS, Boulkeroua WA, Gardiner M, Sarkar A, Maringer M, Oehlmann W, Brenk R, Scherman MS, McNeil M, Rejzek M, Field RA, Singh M, Gray D, Westwood NJ, Naismith JH.

ACS Chem Biol. 2013 Feb 15;8(2):387-96. doi: 10.1021/cb300426u. Epub 2012 Nov 28.

19.

IspE inhibitors identified by a combination of in silico and in vitro high-throughput screening.

Tidten-Luksch N, Grimaldi R, Torrie LS, Frearson JA, Hunter WN, Brenk R.

PLoS One. 2012;7(4):e35792. doi: 10.1371/journal.pone.0035792. Epub 2012 Apr 25.

20.

Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors.

Spinks D, Torrie LS, Thompson S, Harrison JR, Frearson JA, Read KD, Fairlamb AH, Wyatt PG, Gilbert IH.

ChemMedChem. 2012 Jan 2;7(1):95-106. doi: 10.1002/cmdc.201100420. Epub 2011 Dec 8.

21.

Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.

Brand S, Cleghorn LA, McElroy SP, Robinson DA, Smith VC, Hallyburton I, Harrison JR, Norcross NR, Spinks D, Bayliss T, Norval S, Stojanovski L, Torrie LS, Frearson JA, Brenk R, Fairlamb AH, Ferguson MA, Read KD, Wyatt PG, Gilbert IH.

J Med Chem. 2012 Jan 12;55(1):140-52. doi: 10.1021/jm201091t. Epub 2011 Dec 7.

22.

Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3.

Cleghorn LA, Woodland A, Collie IT, Torrie LS, Norcross N, Luksch T, Mpamhanga C, Walker RG, Mottram JC, Brenk R, Frearson JA, Gilbert IH, Wyatt PG.

ChemMedChem. 2011 Dec 9;6(12):2214-24. doi: 10.1002/cmdc.201100344. Epub 2011 Sep 13.

23.

N-myristoyltransferase inhibitors as new leads to treat sleeping sickness.

Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, Stojanovski L, Price HP, Guther ML, Torrie LS, Robinson DA, Hallyburton I, Mpamhanga CP, Brannigan JA, Wilkinson AJ, Hodgkinson M, Hui R, Qiu W, Raimi OG, van Aalten DM, Brenk R, Gilbert IH, Read KD, Fairlamb AH, Ferguson MA, Smith DF, Wyatt PG.

Nature. 2010 Apr 1;464(7289):728-32. doi: 10.1038/nature08893.

24.

Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis.

Torrie LS, Wyllie S, Spinks D, Oza SL, Thompson S, Harrison JR, Gilbert IH, Wyatt PG, Fairlamb AH, Frearson JA.

J Biol Chem. 2009 Dec 25;284(52):36137-45. doi: 10.1074/jbc.M109.045336. Epub 2009 Oct 14.

25.

Resolution of the insect ouabain paradox.

Torrie LS, Radford JC, Southall TD, Kean L, Dinsmore AJ, Davies SA, Dow JA.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13689-93. Epub 2004 Sep 3.

Supplemental Content

Loading ...
Support Center